Recent research highlights a gene associated with Alzheimer’s disease, CASS4, which shows weaknesses in managing the brain’s immune cells tasked with preventing harmful protein accumulation. This discovery provides researchers with a new potential target for slowing Alzheimer’s progression through gene-related therapies, as indicated by a study conducted on mice.
John Lukens, the director at the University of Virginia’s Harrison Family Translational Research Center, discussed the findings with Newsweek. He explained that while CASS4 had been previously identified as a significant risk gene for Alzheimer’s, its broader impact on brain health remained largely unknown.
Our work shows that CASS4 helps to enable microglia to corral and contain neurotoxic amyloid beta aggregates and that its deletion leads to aggravated amyloid plaque spread, damage to neurons, and cognitive decline,Lukens said.
The Brain’s Cleanup System
Alzheimer’s is marked by the buildup of sticky amyloid-beta plaques and twisted tau protein tangles in the brain. Microglia, the brain’s resident immune cells, play a crucial role in addressing this damage.
When functioning properly, microglia can form barriers around amyloid-beta plaques, helping limit damage. The research team managed by Lukens explored CASS4, after various studies recognized it as an Alzheimer’s risk factor, and discovered it aids in regulating microglia responses to these plaques.
In the study, when CASS4 was disrupted in mice, microglia were less effective in managing amyloid-beta plaques, leading to increased plaque spread, neuronal damage, and cognitive decline. The absence of CASS4 also triggered changes in gene activity which might have implications for other diseases like Parkinson’s.
Addie Walsh, the study’s first author, indicated that these findings offer new insights into how this underestimated Alzheimer’s risk gene functions in the brain. These are important findings because they give us new insight into how this understudied Alzheimer’s disease risk gene functions in the brain and suggest that CASS4 may normally help microglia respond to amyloid pathology.
A Possible Treatment Target
Researchers suggest that therapies aimed at enhancing CASS4 activity in microglia might help slow Alzheimer’s progression. Lukens commented on the implications of their work for developing potential treatments:
This work suggests that therapeutics that promote CASS4 function in microglia could provide a novel strategy to limit Alzheimer’s disease progression,Lukens said.
His team is also examining whether CASS4 plays a part in other conditions such as Parkinson’s disease, ALS, and multiple sclerosis. There is an interest in collaborating with UVA’s Manning Institute to develop drugs that target CASS4, potentially leading to clinical trials.
Despite the promise, independent experts warn that mouse studies are just the initial stage of developing treatments. Dr. James Bateman, a behavioral neurologist, highlighted the importance of preclinical findings:
When this gene, CASS4, is experimentally knocked out in mice, it results in a cascade of biological changes resulting in faulty microglia and impaired amyloid plaque clearance. It’s important to remember that preclinical findings are important and critical steps in developing new treatments, but the number of promising findings in pre-clinical models far outweighs successful development of therapies.
The research offers hope for new therapies, but much work remains to transition these findings into actual treatments.
Reference: Lukens, J. R., Walsh, A. E. et al. (2026). Alzheimer’s genetic risk factor CASS4 controls microglial focal adhesion biology and amyloidosis. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20260104. Contact Newsweek editors: Kara Dolman and Paul Donnelley.

The Future of MAHA in American Health Politics
Insulin Cost Caps Gaining Support Amid Rising Prices
A Personal Journey Through Encephalitis
Low-Cost Medication May Benefit Stroke Survivors
The Complex Debate Over Kratom Use in the U.S.
Florida’s Struggle with Dengue Fever and AI Solutions